Core Viewpoint - The era of producing high-value products from CO₂ in the air has arrived, marking significant industrial advancements in the biomanufacturing conversion of carbon-rich gases [1][2]. Group 1: Industrial Challenges and Innovations - The Ministry of Agriculture and Rural Affairs of China has officially approved the use of Debaryomyces hansenii protein as a new feed raw material, representing the first product certificate with independent intellectual property rights derived from CO₂ as the main carbon source [2][4]. - This approval signifies a critical step in the industrial application of this technology, transitioning from laboratory research to practical use [2][4]. - The gas fermentation technology developed by GTLB utilizes inorganic carbon sources (CO₂, CO) to convert them into organic products, overcoming significant industrial challenges [4][6]. Group 2: Production Efficiency and Nutritional Value - The feed protein produced using this gas fermentation technology can achieve production efficiency thousands of times higher than traditional agricultural methods [7]. - A yeast protein factory occupying 150 acres can produce 100,000 tons of high-quality yeast protein annually, equivalent to the output of approximately 600,000 acres of soybean protein [8]. - Yeast protein is recognized for its high and evenly distributed essential amino acid content, rich in trace elements and polysaccharides, making it a safe and high-quality protein source [9]. Group 3: Addressing Resource Shortages - China faces a severe shortage of feed protein resources, with an estimated total consumption of 70 million tons in 2024 and an import dependency exceeding 80%, posing a significant threat to national food security [11]. - The innovative technology aligns with national strategies to develop synthetic biology technologies and explore "artificial protein" as a new food source, aiming to reduce reliance on traditional protein sources like soybean and fishmeal [12]. - The approval of Debaryomyces hansenii protein as a single feed raw material will help create a more sustainable and resource-efficient protein feed supply chain, significantly reducing dependence on land-intensive crops and marine resources [12].

Core Viewpoint - Zhejiang Province is accelerating the innovation and development of the synthetic biology industry, aiming for a total industry scale of 150 billion by 2027, with core enterprises achieving a production value of 20 billion [1][2]. Group 1: Industry Development Plan - The "Implementation Plan for Accelerating the Innovation and Development of the Synthetic Biology Industry in Zhejiang Province" outlines six major development directions, eleven regional industrial layouts, key tasks for nine universities and research institutes, and ten core technology breakthroughs [1][2]. - The plan aims to establish an internationally influential synthetic biology industry innovation development hub in Zhejiang [1]. Group 2: Alliance Formation - The Zhejiang Synthetic Biology Industry Technology Alliance, guided by the Zhejiang Provincial Department of Economy and Information Technology, is a non-profit organization initiated by Zhejiang University Hangzhou International Innovation Center, aiming to promote technological innovation and industry cultivation [2]. - The alliance will leverage the advantages of Zhejiang University in talent cultivation, technological innovation, and high-level platforms to support the synthetic biology industry [2]. Group 3: Research and Development Facilities - The Zhejiang University Hangzhou International Innovation Center has established the Bio and Molecular Manufacturing Research Institute and the iBioFoundry, the largest and most integrated automated high-throughput scientific device in the field globally [4]. - This facility enables full-process automation from sample intelligent access to product detection and is now open as a shared research platform for teams and enterprises [4]. Group 4: Upcoming Conference - The 2025 Fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on AI and biological manufacturing, as well as four application areas: green chemicals and new materials, future food, future agriculture, and beauty raw materials [6][8]. - The conference aims to explore the development trends of the bio-manufacturing industry and promote the transfer and transformation of scientific and technological achievements [6].

Group 1 - Industry Investment Rating: Overweight [1] - Core Viewpoint: The chemical sector's overall performance ranked 16th with a fluctuation of 0.80%, underperforming the Shanghai Composite Index by 0.60 percentage points [4][22] - Key Recommendations: Focus on synthetic biology, pesticides, chromatography media, sugar substitutes, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [4] Group 2 - Synthetic Biology: A pivotal moment is approaching, with low-energy products expected to gain a longer growth window due to the energy structure adjustment [4] - Refrigerants: The third-generation refrigerants are entering a high prosperity cycle, with supply constraints and stable demand growth anticipated [5] - Electronic Specialty Gases: The domestic market faces a contradiction between rapid upgrades in wafer manufacturing and insufficient high-end electronic specialty gas capacity, presenting significant domestic substitution opportunities [6][8] - Light Hydrocarbon Chemicals: A global trend towards lighter raw materials in the olefin industry is noted, with a shift from heavy naphtha to lighter ethane and propane [8] - COC Polymers: The domestic industrialization process is accelerating, driven by breakthroughs in local enterprises and a shift in downstream industries to domestic production [9] - Potash Fertilizer: Prices are expected to bottom out and rebound due to supply reductions and increased demand from farmers [10] - MDI Market: The oligopoly structure is expected to improve, with demand steadily increasing and a favorable supply outlook anticipated [12]

Core Viewpoint - Micro Yuan Synthetic's allulose has received administrative approval from the National Health Commission, making it the first company in China to produce allulose through a biological fermentation process, which is a significant milestone in the synthetic biology industry [1][3]. Company Summary - Micro Yuan Synthetic has developed a unique "one-step fermentation method" for producing allulose, increasing conversion efficiency to 80% and reducing production costs by 50% [3]. - The AS10 strain used in production is described as an "intelligent cell factory" that can be infinitely replicated, promoting the industrial adaptation of engineered strains [3]. - The company aims to make allulose a widely used health sugar, addressing the domestic sugar supply gap while being beneficial for blood sugar control and weight management [1][2]. Industry Summary - The global focus on obesity and diabetes has led the pharmaceutical industry to seek safe sugar alternatives, with allulose being viewed as a promising candidate for large-scale application [2]. - The synthetic biology manufacturing sector is expanding into various fields, including biomedicine, food nutrition, and new materials, with significant policy support from local governments [5][6]. - The innovative production methods in synthetic biology not only enhance efficiency but also contribute to environmental sustainability by reducing land use and production costs [4][6].

Core Viewpoint - Guangdong Zhumei Biotechnology has achieved a significant breakthrough in the industrialization of natural high-intensity sweet protein by completing the first domestic pilot test of recombinant Brazzein using Pichia pastoris as the chassis cell, aiming for ton-level production capacity by 2026, which will greatly increase the yield of Brazzein [1][2]. Group 1: Characteristics of Brazzein - Brazzein is derived from the fruit of a wild plant in West Africa and is known to be 500-2000 times sweeter than sucrose, making it one of the sweetest natural substances known to humans [4]. - It maintains stability across a pH range of 2.5-8 and retains its sweetness even after being heated at 80°C for 4 hours or 98°C for 2 hours [5]. - As a protein, Brazzein is easily digested into amino acids, has no impact on blood sugar, and poses no health risks [6]. - It offers a clean taste similar to sucrose without metallic or bitter aftertastes, making it suitable for widespread application in the food industry [6]. - Research indicates that Brazzein may possess anti-inflammatory and antioxidant properties, with similarities to antimicrobial peptides, providing some antibacterial and antifungal activity [6]. Group 2: Market Potential and Challenges - The global market for Brazzein was valued at $500 million in 2023 and is projected to reach $790 million by 2029 [7]. - Traditional extraction methods yield very low extraction rates (~0.2%), making precision fermentation and genetic engineering the most promising methods for developing Brazzein [7]. - Current microbial expression systems face challenges such as low protein expression levels, incorrect protein folding leading to reduced activity, and complex, costly purification processes, which limit the widespread application of sweet proteins [9]. Group 3: Industry Developments - In May 2023, Sweegen successfully produced Brazzein using precision fermentation and became the first to receive FEMA GRAS certification [11]. - In 2024, Oobli's Brazzein production received FDA GRAS certification for general food applications, and they announced a partnership with Ingredion to advance sweet protein applications [11]. - Ginkgo Bioworks and GreenLab are collaborating to enhance Brazzein expression in corn and scale up production through precision fermentation [11]. - Waterdrop Farm also achieved FDA SELF-GRAS status in March 2025, becoming one of the few companies to commercialize Brazzein [11]. Group 4: Company Overview - Guangdong Zhumei Biotechnology is a high-tech enterprise specializing in the research, production, and sales of synthetic biology products, with a 1000 square meter intelligent research center [12]. - The company utilizes synthetic biology technology to efficiently produce various products, including recombinant human collagen, astaxanthin, beta-carotene, antimicrobial peptides, and lysozyme [12].

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities Synthetic Biology Index, which includes 58 companies across various sectors, has seen a decline of 3.42% recently, underperforming compared to the Shanghai Composite Index and the ChiNext Index [5][17] - The first local regulations for synthetic biology manufacturing were passed in Changde, Hunan, aimed at promoting industry development and addressing issues like talent shortages and approval efficiency [8][10] Summary by Sections 1.1 Secondary Market Performance - The synthetic biology sector's stocks have shown poor performance, with a recent decline of 3.42%, ranking 32nd among sectors [17] - The top-performing companies include Jincheng Pharmaceutical (+11%), Xinhai Hengli (+10%), and Dongbao Biological (+7%) [18] 1.2 Company Business Progress - Kexin Pharmaceutical's CAR-T therapy targeting Claudin18.2 has received regulatory acceptance for market application, offering new treatment options for advanced gastric cancer patients [23] - Angel Yeast announced a significant investment of 5.56 billion yuan to expand its biological manufacturing center and enhance its product lines [23] - Internationally, Covestro acquired Swiss film technology company Pontacol to strengthen its specialty materials business [25] 1.3 Industry Financing Tracking - The synthetic biology sector is witnessing accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [31] - Zhejiang Rongrui Technology completed nearly 100 million yuan in Pre-A financing, focusing on green biological manufacturing [31] - Avantium, a Dutch biobased PEF company, secured 10 million euros to alleviate short-term liquidity pressures [31]

Group 1 - The company plans to issue A-shares to specific investors, pending approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission (CSRC) [2][3][4] - The final issuance price will be no less than 85% of the average trading price of the company's shares over the 20 trading days prior to the pricing date [3][4][5] - The total number of shares to be issued will not exceed 25% of the company's total share capital, amounting to a maximum of 83,530,821 shares [5][6] Group 2 - The funds raised will be allocated to specific projects, including the construction of a production base for amino acids and an enhancement project for raw materials [6][7] - The company may adjust the investment priorities and amounts based on the actual net amount raised and project urgency if the net proceeds are less than planned [6][7] - The company has committed to using the raised funds in compliance with relevant regulations and will replace any pre-invested funds once the raised funds are available [6][7] Group 3 - The company operates in the pharmaceutical industry, which is subject to strict regulatory oversight from various government bodies, including the National Medical Products Administration and the National Healthcare Security Administration [19][20] - The pharmaceutical industry is characterized by significant competition and regulatory challenges, including drug approval processes and pricing regulations [19][20][21] - The company’s business encompasses pharmaceutical distribution, manufacturing, and health services, with a focus on both commercial and industrial sectors [19][20]

Core Viewpoint - The article highlights the upcoming "Youth Forum on Biomanufacturing" scheduled for August 20 in Ningbo, Zhejiang, as part of the SynBioCon 2025 event, aimed at promoting innovation and collaboration in the field of synthetic biology and biomanufacturing [2][3]. Group 1: Event Details - The "Youth Forum on Biomanufacturing" will focus on addressing scientific issues, solutions, achievements, scalability, and future directions in the research field [3]. - The event will take place on August 20, 2025, with limited seating available (only 30 seats) [6]. - Participants can choose to register for either the Youth Forum or the Technology Achievement Showcase [6]. Group 2: Participation and Contributions - The event encourages universities and research institutions to apply for sharing their innovative achievements [4]. - SynBioCon 2025 will also feature a "Technology Achievement Showcase" to publicly collect 100 innovative achievements and projects in the field of synthetic biology and biomanufacturing for on-site display and networking [6]. Group 3: Organizers and Previous Events - The event is organized by Ningbo Detaizhongyan Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [11]. - Previous editions of the SynBioCon were successfully held in 2022, 2023, and 2024 in Ningbo, showcasing the growing interest and development in the field [13].

Core Viewpoint - Meihua Biotech has successfully completed the acquisition of the amino acid business and assets from Concord Fermentation, enhancing its product and business structure in the synthetic biology sector [1]. Group 1: Acquisition Details - The acquisition was finalized on July 1, 2025, with a transaction price of approximately 16.8 billion Japanese yen, equivalent to about 833 million RMB [1]. - The final transaction price was adjusted based on the cash reserves and working capital of the target assets at the time of closing, which included an estimated cash amount of 11.3 billion Japanese yen (approximately 560 million RMB) [1]. - Concord Fermentation is recognized as a leader in biotechnology and fermentation, focusing on high-quality amino acids and other synthetic biology products [1]. Group 2: Business Expansion - The acquisition allows Meihua Biotech to diversify its product offerings by adding various new amino acid products and strains, enhancing its fermentation and refinement capabilities for high-value pharmaceutical amino acids [1]. - The company will also gain production capabilities and intellectual property for three types of Human Milk Oligosaccharides (HMO) through the integration of a precision fermentation platform [1]. - The acquisition supports the company's strategy to expand its industrial footprint internationally by acquiring multiple domestic and foreign operational entities [1]. Group 3: Financial Performance - In Q1 2025, the feed amino acid segment generated revenue of 2.939 billion RMB, accounting for approximately 46.9% of total revenue, marking a year-on-year increase of 6.68% [2]. - The growth in this segment is attributed to the rise in both volume and price of lysine, as well as increased sales of threonine, positioning it as a potential new growth driver for the company [2].

中化新网讯 6月26日，中国科学院院士、天津大学教授元英进，合成生物学领军者约翰·康伯斯，欧洲科 学院院士、曼彻斯特大学教授蔡毅之，与天津大学历届iGEM团队成员在津共聚"iGEM中国20年"学术论 坛，共同探讨合成生物学未来发展方向。 约翰·康伯斯在活动中做了题为"合成生物学：通过基因读、写、编辑打造可持续的未来"的报告。他指 出，过去十年间，合成生物学已从一个小众科学领域发展成为潜力巨大的活跃产业，从基因编辑到合成 基因组学等关键技术的进步，推动了制药、农业、材料及能源等行业的可持续发展与创新。他还表示， 初创企业与风险投资的进入起到了加速创新的作用，有助于构建可持续的生物经济体系，学术界、产业 界与政府间的全球协作也在加速这一进程。 天津大学作为最早把这项国际赛事引入中国的高校，也开设了"基因组设计合成"这门本科生课程，并于 2017年设立合成生物学专业，开始招收本科生；2025年成立合成生物学院。经过十几年的发展，天津大 学合成生物学从零起步走到世界科技前沿，牵头建设合成生物技术全国重点实验室，近三年合成生物学 领域研究论文发表量居全球第一。 iGEM竞赛是合成生物学领域的国际顶级学术性竞赛，最早由美 ...